Earnings Call Summary | Intelgenx Technologies Corp.(IGXT.US) Q4 2023 Earnings Conference
Earnings Call Summary | Intelgenx Technologies Corp.(IGXT.US) Q4 2023 Earnings Conference
The following is a summary of the IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript:
以下是英特爾GenX科技公司（IGXT）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
IntelGenx reported Q4 total revenue of $426,000, a 146% increase compared to Q4 of 2022.
Operating costs and expenses were $2.4 million for Q4 2023, down from $2.7 million for the same period in 2022.
Operating loss was $2 million for Q4 2023, down from $2.5 million in the Q4 2022.
The net comprehensive loss for the full year 2023 was $10.1 million or $0.06 per share for 2023, compared to $11.5 million or $0.07 per share for 2022.
As of December 31, 2023, the company's cash and short-term investments totaled $2.3 million.
Revenue projection between $200,000 and $300,000 from initial order of 400,000 films from Tilray is anticipated.
Despite no specific guidance, several million dollars in revenue is expected from RIZAFILM.
The company is currently raising between $10 to $20 million, with the first round planned to close upon reaching $2 or $3 million.
IntelGenX報告稱，第四季度總收入爲42.6萬美元，與2022年第四季度相比增長了146％。
2023年第四季度的運營成本和支出爲240萬美元，低於2022年同期的270萬美元。
2023年第四季度的營業虧損爲200萬美元，低於2022年第四季度的250萬美元。
2023年全年的淨綜合虧損爲1,010萬美元，合每股虧損0.06美元，而2022年爲1150萬美元，合每股虧損0.07美元。
截至2023年12月31日，該公司的現金和短期投資總額爲230萬美元。
預計從Tilray最初訂購的40萬部電影的收入將在20萬至30萬美元之間。
儘管沒有具體的指導方針，但預計RIZAFILM將帶來數百萬美元的收入。
該公司目前正在籌集1000萬至2000萬美元的資金，第一輪融資計劃在達到200萬美元或300萬美元時結束。
Business Progress:
業務進展：
IntelGenx commenced production of RIZAFILM in December 2023 and expects to ship the product to Gensco in Q2 2024 for immediate market launch.
A new commercial partner for RIZAPORT is being sought to maximize its success in the European market.
Completion of updated formulation work for CBD20, THC10, and a combined CBD-THC is expected between May and June.
Business deals were secured, evident in the development and licensing agreements with a subsidiary of Covenant Animal Health.
RIZAFILM in the USA and a new partner for RIZAPORT in Europe are planned to be launched in 2024.
Dosing has started in the Montelukast VersaFilm IIa clinical trial. Initial results for a Phase II clinical trial in patients with Parkinson's disease is expected by the current quarter's end.
A Reg A offering of up to 2 million shares of non-traded Series A convertible cumulative preferred stock at $10 per share is planned for launch.
The company's main short-term focus points are the launches of RIZAFILM and buprenorphine.
Business strategies include pursuing contracts for its CDMO, which will oversee initial development work for specific molecules while retaining manufacturing rights.
Looking ahead, IntelGenx anticipates a facility expansion within '25 or '26, with funding options including bank loans, government support, or partnering support being considered.
IntelGenX 於 2023 年 12 月開始生產 RIZAFILM，預計將於 2024 年第二季度將該產品交付給 Gensco，以便立即上市。
正在尋找RIZAPORT的新商業合作伙伴，以最大限度地提高其在歐洲市場的成功。
CBD20、THC10 和 CBD-THC 組合的更新配方工作預計將在五月至六月之間完成。
商業交易得到了保障，這在與Covenant Animal Health子公司的開發和許可協議中顯而易見。
美國的RIZAFILM和RIZAPORT在歐洲的新合作伙伴計劃於2024年推出。
Montelukast VersaFilm IIa臨床試驗已開始給藥。一項針對帕金森氏病患者的II期臨床試驗的初步結果預計將在本季度末公佈。
Reg A計劃以每股10美元的價格發行高達200萬股非交易的A系列可轉換累積優先股。
該公司的主要短期重點是推出RIZAFILM和****。
業務戰略包括爲其CDMO簽訂合同，該組織將監督特定分子的初始開發工作，同時保留製造權。
展望未來，IntelGenx預計將在25年或26年內擴建設施，並考慮包括銀行貸款、政府支持或合作支持在內的融資方案。
More details: Intelgenx Technologies Corp. IR
更多詳情： 英特爾傑克斯科技公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。